Novartis AG

NOVN

CH0012005267

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

09:00pm - American Society of Hematology Meeting - Abstract Number - 3178

More about the company

Income Statement and Estimates

income-statement-evolution-chart NOVARTIS-AG

More financial data

Analysis / Opinion

NOVARTIS : Q3 beat and a guidance upgrade; today’s dip is a buying opportunity

October 29, 2024 at 02:16 pm EDT

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

101.93USD

Average target price

115.73USD

Spread / Average Target

+13.54%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Swiss Exchange Other stock markets 11:30:51 2024-12-09 am EST			5-day change	1st Jan Change
89.38 ^CHF	-0.48%		-4.17%	+5.31%

04:00pm	Novartis AG - Special Call
08:44am	Novartis: positive long-term data in leukemia	CF

Novartis AG - Special Call	10:00am
Novartis: positive long-term data in leukemia	02:44am	CF
Novartis Logs Superior Efficacy Results in Longer-term Data for Leukemia Treatment	11:26pm	MT
Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix	Dec. 08	CI
Swiss Market Index Ends Week Little Changed; Holcim Shares Down	Dec. 06	MT
Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy	Dec. 06	MT
Novartis: positive data for Fabhalta in HPN	Dec. 06	CF
Novartis' Rare Blood Disorder Drug Improves Hemoglobin Levels in Phase 3b Trial	Dec. 06	MT
New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy	Dec. 06	DJ
Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta	Dec. 06	CI
NOVARTIS AG : Deutsche Bank remains Neutral	Dec. 05	ZD
US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version	Dec. 04	MT
Novartis cannot block generic of best-selling heart drug, US appeals court says	Dec. 04	RE
HSBC Downgrades Novartis to Reduce, Price Target is $95	Dec. 04	MT
NOVARTIS AG : JP Morgan reiterates its Neutral rating	Dec. 03	ZD
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 02	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate	Dec. 02	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
Novartis AG, PTC Therapeutics, Inc. - M&A Call	Dec. 02
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement	Dec. 02	MT
PTC Therapeutics Shares Jump on Pact With Novartis	Dec. 02	DJ
PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket	Dec. 02	MT

Novartis AG

Equities